PATIZRA 10 MG/ML PARENTERAL ORDINARY VIALS Uganda - angļu - National Drug Authority

patizra 10 mg/ml parenteral ordinary vials

nvs kenya ltd - ranibizumab - parenteral ordinary vials - 10 mg/ml

LUCENTIS kit for intravitreal injection 10mg/mL [age-related macular degeneration associated with subfoveal choroidal neovascularization] (ルセンティス硝子体内注射用キット10mg/mL［中心窩下脈絡膜新生血管を伴う加齢黄斑変性症］) Japāna - angļu - すりの適正使用協議会 RAD-AR Council, Japan

lucentis kit for intravitreal injection 10mg/ml [age-related macular degeneration associated with subfoveal choroidal neovascularization] (ルセンティス硝子体内注射用キット10mg/ml［中心窩下脈絡膜新生血管を伴う加齢黄斑変性症］)

novartis pharma k.k. - ranibizumab(genetical recombination) - injection

LUCENTIS kit for intravitreal injection 10mg/mL [macular edema following retinal vein occlusion, choroidal neovascularisation in pathologic myopia, diabetic macular edema] (ルセンティス硝子体内注射用キット10mg/mL［網膜静脈閉塞症に伴う黄斑浮腫、病的近視における脈絡膜新生血管、糖尿病黄斑浮腫］) Japāna - angļu - すりの適正使用協議会 RAD-AR Council, Japan

lucentis kit for intravitreal injection 10mg/ml [macular edema following retinal vein occlusion, choroidal neovascularisation in pathologic myopia, diabetic macular edema] (ルセンティス硝子体内注射用キット10mg/ml［網膜静脈閉塞症に伴う黄斑浮腫、病的近視における脈絡膜新生血管、糖尿病黄斑浮腫］)

novartis pharma k.k. - ranibizumab(genetical recombination) - injection

LUCENTIS solution for intravitreal injection 10mg/mL [age-related macular degeneration associated with subfoveal choroidal neovascularization] (ルセンティス硝子体内注射液10mg/mL［中心窩下脈絡膜新生血管を伴う加齢黄斑変性症］) Japāna - angļu - すりの適正使用協議会 RAD-AR Council, Japan

lucentis solution for intravitreal injection 10mg/ml [age-related macular degeneration associated with subfoveal choroidal neovascularization] (ルセンティス硝子体内注射液10mg/ml［中心窩下脈絡膜新生血管を伴う加齢黄斑変性症］)

novartis pharma k.k. - ranibizumab(genetical recombination) - injection

LUCENTIS solution for intravitreal injection 10mg/mL [macular edema following retinal vein occlusion, choroidal neovascularisation in pathologic myopia, diabetic macular edema] (ルセンティス硝子体内注射液10mg/mL［網膜静脈閉塞症に伴う黄斑浮腫、病的近視における脈絡膜新生血管、糖尿病黄斑浮腫］) Japāna - angļu - すりの適正使用協議会 RAD-AR Council, Japan

lucentis solution for intravitreal injection 10mg/ml [macular edema following retinal vein occlusion, choroidal neovascularisation in pathologic myopia, diabetic macular edema] (ルセンティス硝子体内注射液10mg/ml［網膜静脈閉塞症に伴う黄斑浮腫、病的近視における脈絡膜新生血管、糖尿病黄斑浮腫］)

novartis pharma k.k. - ranibizumab(genetical recombination) - injection

LUCENTIS solution for intravitreal injection 10mg/mL [retinopathy of prematurity] (ルセンティス硝子体内注射液10mg/mL［未熟児網膜症］) Japāna - angļu - すりの適正使用協議会 RAD-AR Council, Japan

lucentis solution for intravitreal injection 10mg/ml [retinopathy of prematurity] (ルセンティス硝子体内注射液10mg/ml［未熟児網膜症］)

novartis pharma k.k. - ranibizumab(genetical recombination) - injection

Ravegza 2.3 mg per 0.23 ml Solution for injection Saūda Arābija - angļu - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

ravegza 2.3 mg per 0.23 ml solution for injection

ms pharma saudi (msps), saudi arabia - ranibizumab - solution for injection - 10 mg/ml,

Eylea Eiropas Savienība - angļu - EMA (European Medicines Agency)

eylea

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - eylea is indicated for adults for the treatment of:neovascular (wet) age-related macular degeneration (amd);visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo);visual impairment due to diabetic macular oedema (dme);visual impairment due to myopic choroidal neovascularisation (myopic cnv).

Beyfortus Eiropas Savienība - angļu - EMA (European Medicines Agency)

beyfortus

astrazeneca ab - nirsevimab - immune sera and immunoglobulins, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season.beyfortus should be used in accordance with official recommendations.

EYLEA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 2MG Singapūra - angļu - HSA (Health Sciences Authority)

eylea solution for injection in prefilled syringe 2mg

bayer (south east asia) pte ltd - aflibercept - injection, solution - 2.0mg/50mcl - aflibercept 2.0mg/50mcl